AzTrials
AzTrials

Apical LesionNCT07876427

The Effect of Injectable Platelet Rich Fibrin on Apical Lesion Healing

A study testing i-PRF and root canal treatment and intracanal medicament in people with Apical Lesion, run by Hande Has Elçi at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In recent years, the use of autologously obtained blood products that stimulate cell proliferation, such as platelet-rich plasma (PRP) and platelet-rich fibrin (PRF), has become increasingly widespread. Numerous studies have been published on PRF, which comes in many different forms. Read more about this study

Who is it for?
Ages 16 to 75 yearsHealthy volunteers can take part
Conditions the study is for
Apical Lesion
What is being tested?
i-PRF and root canal treatment and intracanal medicament
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
36 participants
Where
1 siteTurkey (Türkiye)
Study dates
1 Sep 2025to 2 Oct 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 16 to 75 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Who may be able to join

  • Individuals over 16 years of age
  • Individuals with apical lesions of 3-10 mm in diameter in single-rooted teeth
  • Individuals not using anticoagulants

Who cannot join

  • 1. Individuals with uncontrolled diabetes or HbA1c >7
  • 2. Pregnant or breastfeeding women,
  • 3. Individuals using oral contraceptives,
  • 4. Individuals with lesions in multi-rooted teeth

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Harran University Faculty of Dentistry

    Sanliurfa, 63300

Other trials in Turkey (Türkiye)

About this study

Official title: Six-Month Follow-Up of the Effect of Injectable Platelet-Rich Fibrin Injection on Periapical Lesion Treatment

In recent years, the use of autologously obtained blood products that stimulate cell proliferation, such as platelet-rich plasma (PRP) and platelet-rich fibrin (PRF), has become increasingly widespread. Numerous studies have been published on PRF, which comes in many different forms. I-PRF, an injectable form, requires a lower cycle time and has a higher growth factor. Conventional root canal treatment remains effective in the treatment of periapical lesions. However, the treatment course can vary, and lesion size may remain constant even after the termination of root canal treatment, even if symptoms resolve. Therefore, our study aimed to achieve greater bone trabeculation and a greater reduction in lesion size compared to conventional treatment in the treatment of relatively large lesions (0.3-1 cm) by injecting I-PRF into the apical lesion area at several points and in three sessions. To this end, to more clearly demonstrate healing and to examine trabeculations in detail, cone-beam computed tomography images will be obtained on the day the apical lesions are diagnosed (day 1) and at the second follow-up appointment (month 6). If our study results are significant, it will be possible to salvage teeth with apical lesions, often considered for extraction, with a cost-effective treatment option.

Read the detailed description

Although conventional endodontic approaches generally achieve high success rates in the treatment of periapical lesions, treatment outcomes may vary depending on several factors. In particular, lesion size, the patient's systemic condition, and the treatment protocol employed may directly influence the healing process and treatment success. Healing may be prolonged, and the response to treatment may be more limited in cases involving large lesions or immunocompromised individuals. In this context, the adjunctive application of injectable platelet-rich fibrin (i-PRF) alongside conventional root canal treatment may offer a biologically innovative contribution to existing treatment protocols.

The use of autologous therapies in dentistry has increased in recent years because of their potential to facilitate natural healing, accelerate tissue regeneration, and improve postoperative patient comfort. Platelet-rich fibrin (PRF) and platelet-rich plasma (PRP) are among the autologous products used for this purpose. Platelets play an important role in wound healing. Upon activation, they release various growth factors, including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and insulin-like growth factor I (IGF-I), which stimulate cell proliferation. In 2014, injectable platelet-rich fibrin (i-PRF) was developed by modifying centrifugation parameters. Centrifugation of blood at lower speeds in non-glass centrifuge tubes results in the formation of a fluid PRF product known as i-PRF. Owing to its growth factors and bioactive proteins, i-PRF may promote tissue regeneration, enhance angiogenesis and local blood supply, and modulate the inflammatory response, potentially contributing to the reduction of symptoms such as pain and swelling.

In addition to releasing growth factors and cytokines derived from platelets and leukocytes, which play critical roles in healing processes such as collagen matrix formation and neovascularization, PRF may also support immune responses and tissue epithelialization. The fibrin component of PRF serves as a scaffold, while leukocytes, macrophages, neutrophils, and platelets help recruit and accumulate regenerative cells at defect sites. Furthermore, fibrin acts as a reservoir for growth factors, allowing their gradual release over a period of approximately 10-14 days.

PRF has also been reported to exert antimicrobial effects through the secretion of pro-inflammatory and anti-inflammatory cytokines. Its application has been associated with reduced postoperative pain scores. Studies using the visual analogue scale (VAS) have demonstrated statistically significant reductions in pain following PRF application.

In a study by Sitamahalakshmi et al., i-PRF was applied during flap surgery for the treatment of infrabony defects. The authors reported an increase in bone levels at 6 months compared with baseline. These findings suggest a potential beneficial effect of i-PRF on bone healing and support the rationale underlying our hypothesis. However, unlike that study, the present investigation does not involve a surgical procedure.

Faour et al. investigated individuals with thin gingival phenotypes and used a 30-gauge microneedle, as in our study. They reported an increase in gingival thickness at 3 months. These findings suggest that i-PRF may have beneficial effects on local tissues. Unlike that study, the primary outcomes of our investigation are periapical lesion volume reduction and increased bone trabeculation. Nevertheless, an increase in the thickness of the soft tissues surrounding the tooth may have implications for the supporting periodontal tissues and potentially contribute to long-term tooth preservation.

In an ex vivo study conducted by Panda et al. in 2024, both leukocyte- and platelet-rich fibrin (L-PRF) and i-PRF were shown to increase the number of dental pulp stem cells. The study also demonstrated that PRF groups produced an extracellular matrix containing calcium-rich deposits through osteoblast activity. Based on these findings, we hypothesize that i-PRF injected into the periapical region may contribute to the repair of the periapical bone defect through similar biological mechanisms.

The minimally invasive nature of microneedle-based administration, the possibility of monitoring healing using objective methods such as radiographic and fractal analyses, and its potential to support both endodontic and periodontal healing represent clinically relevant features of this approach. In particular, i-PRF-assisted treatment protocols may warrant further investigation as a potential adjunctive approach in complex clinical situations, including cases involving extensive periapical defects, lesions that respond poorly to conventional treatment, and situations requiring bone regeneration before implant placement. The findings of this study are expected to contribute to the development of more effective, biologically based approaches to the treatment of periapical lesions.

Study Hypothesis Based on the aforementioned evidence, the hypothesis of this study is that the administration of i-PRF injections as an adjunct to conventional root canal treatment will result in greater periapical healing and increased bone trabeculation than conventional root canal treatment alone, owing to the growth factors and other bioactive components contained in i-PRF.

Originality and Novelty of the Project Although i-PRF has previously been used in endodontic treatment through intracanal application, the present study will investigate its injection into the tissues surrounding the periapical lesion.

To the best of our knowledge, the needle gauge and length planned for use in this study have previously been reported in the context of periodontal treatment, specifically microneedling to increase the width of keratinized gingiva, rather than for the treatment of periapical lesions.

To the best of our knowledge, the use of an ultrafine, short needle (30 G, 4 mm) to deliver i-PRF atraumatically into the periapical region, with the aim of promoting healing of lesions that might otherwise be considered for surgical intervention while minimizing local tissue irritation, has not previously been reported in the literature.

To the best of our knowledge, this will be the first study to investigate the injection of i-PRF into the tissues surrounding a periapical lesion through an apical approach.

Despite being an exploratory investigation of a novel approach, the study has been designed to incorporate a comprehensive assessment of healing. In addition to evaluating radiographic outcomes using cone-beam computed tomography (CBCT), one of the most detailed imaging modalities available for assessing periapical lesions, the study will record clinical parameters, including the width of keratinized gingiva, VAS pain scores, percussion sensitivity, tooth mobility, and periodontal probing depth at the tooth under investigation. By integrating detailed radiographic assessment with relevant clinical parameters, this study aims to provide preliminary evidence regarding a novel adjunctive treatment approach for periapical lesions and to inform the design of future clinical investigations.

Conditions
Apical Lesion
Being tested
i-PRF, root canal treatment and intracanal medicament
Keywords
root canal treatment, i-PRF, apical lesion healing

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • i-PRFOther

    Both groups underwent root canal treatment. In the study group, i-PRF injections derived from the patient's own blood were administered to the root apex of the relevant tooth. The differences were that it was performed using microneedling and applied without opening a flap.

  • root canal treatment and intracanal medicamentOther

    A two-stage standard root canal treatment was performed.

Study groups in NCT07876427
Study groupRoleWhat they receive
control groupActive comparatorTwo-stage root canal treatment was performed; however, i-PRF injection was not administered.
Receives: Other: root canal treatment and intracanal medicament
study groupExperimentalTwo-stage root canal treatment and i-PRF injection with microneedling were performed.
Receives: Other: i-PRF; Other: root canal treatment and intracanal medicament

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. reduction in lesion volume

    As a result of treatments, the radiographic lesion volume decreased compared to baseline at the sixth month.

    Measured: 6 month

Secondary outcomes (1)
  1. keratinized gingival width

    As a result of treatments, keratinized gingiva is regained at the sixth month compared to the baseline.

    Measured: 6 month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Oct 2026
  2. Study start1 Sep 2025
  3. Primary completion15 Jul 2026
  4. Study completion2 Oct 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
36 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07876427
Sponsor's protocol ID
HRÜ/25.14.13
Status last verified
Oct 2026
First submitted
9 Oct 2026
Last updated
15 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing i-PRF and root canal treatment and intracanal medicament in people with Apical Lesion, run by Hande Has Elçi at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

reduction in lesion volume (time frame: 6 month). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in